← Back to Search

Alkylating Agent

Olaparib plus carboplatin and paclitaxel for Ovarian Cancer

Phase 1 & 2
Waitlist Available
Led By Saul Rivkin, MD
Research Sponsored by Swedish Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
All Individual Drugs Already Approved
Approved for 10 Other Conditions
No Placebo-Only Group

Summary

The purpose of this study is to determine the maximum tolerated dose (MTD) of the investigational agent, olaparib, to give in combination with carboplatin and paclitaxel in patients with relapsed ovarian cancer or uterine cancer. Furthermore, the investigators intend to study the safety and tolerability of the study treatment, response to treatment, time to disease progression, and overall survival.

Eligible Conditions
  • Ovarian Cancer
  • Uterine Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 10 Other Conditions
This treatment demonstrated efficacy for 10 other conditions.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Olaparib plus carboplatin and paclitaxelExperimental Treatment3 Interventions
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Paclitaxel
FDA approved
Carboplatin
FDA approved
Olaparib
FDA approved

Find a Location

Who is running the clinical trial?

Swedish Medical CenterLead Sponsor
54 Previous Clinical Trials
8,442 Total Patients Enrolled
AstraZenecaIndustry Sponsor
4,390 Previous Clinical Trials
289,109,083 Total Patients Enrolled
47 Trials studying Ovarian Cancer
23,672 Patients Enrolled for Ovarian Cancer
Saul Rivkin, MDPrincipal InvestigatorSwedish Medical Center Cancer Institute
1 Previous Clinical Trials
30 Total Patients Enrolled
~4 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top